Genotype and phenotype patterns of drug-resistant HIV-1 subtype B′ (Thai B) isolated from patients failing antiretroviral therapy in China

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 1, 2007, Pages 14-19

  Ma, Liying ^a   Sun, Jianping ^a   Xing, Hui ^a   Si, Xuefeng ^a   Yuan, Lin ^a   Guo, Yanfang ^a   Cheng, Hua ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Drug resistance; Genotype; HIV 1; Phenotype

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; GENE PRODUCT; K103N PROTEIN; NEVIRAPINE; NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; Y181C PROTEIN; ZIDOVUDINE;

ADULT; ARTICLE; CHINA; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHINA; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; PHENOTYPE;

EID: 33845980597     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000243049.27580.cc     Document Type: Article

References (20)

1. Fauci AS. HIV and AIDS: 20 years of science. Nat Med. 2003;9:839-843.
2. Chinese Government Official Web Portal. 650,000 HIV Victims in China: Assessment. Available at: http://english.gov.cn/2006-01/25/content_171150.htm. Accessed May 5, 2006.
3. Xinhuanet. What is "Four Free, One Care"? Available at: http://news.xinhuanet.com/ newscenter/ 2004-12/01/content_2281179.htm. 2006). Accessed May 15, 2006.
4. Li JY, Li HP, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res. 2005;15:843-849.
5. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-1401.
6. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://aidsinfor.nih.gov. Accessed May 18, 2006.
7. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41-48.
8. Platt EJ, Wehrly K, Kuhmann SE, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:2855-2864.
9. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
10. Peeters M, Liegeois F, Torimiro N, et al. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol. 1999;73:7368-7375.
11. Sarmati L, Nicastri E, Parisi SG, et al. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. J Clin Microbiol. 2002;40:335-340.
12. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis. 2001;32:774-782.
13. Yang HT, Xing H, Jia CM, et al. A molecular epidemiological study on the human immunodeficiency virus infection in Jiangsu province. Zhonghua Liu Xing Bing Xue Za Zhi. 2003;24:976-979.
14. Su B, Liu L, Wang F, et al. HIV-1 subtype B′ dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS. 2003;17:2515-2520.
15. Zhang L, Chen Z, Cao Y, et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol. 2004;78:13591-13599.
16. Simparak W, Kositanont U, Sutthent R, et al. HIV-1 subtyping using gag/env heteroduplex mobility assay and peptide enzyme-linked immunosorbent assay. Asian Pac J Allergy Immunol. 2005;23:143-152.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:215-221.
18. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis. 2000;181:904-911.
19. Shulman N, Winters M. A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors. Curr Drug Targets Infect Disord. 2003;3:273-281.
20. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev. 2004;6:123-130.